Table 1.

Case characteristics

Case ID	Sex (M/F)	AN1792 dose (μg)	Injections (nr.)	Antibody response (mean titre)	Survival time from first immunization (months)	Dementia duration (years)	Age at death (years)	Time of death (year)	Cause of death (as per formal death certificate)	Neuropathology findings			Post-mortem interval (hours)	Braak stages	Evidence of plaque removala	APOE ε4 allele (copy nr.)
										ABC scores	CAA	Other
iAD
102-1	F	50	5	119	20	6	74	2002	Pulmonary embolism, DVT, neurological disorder	A3B3C3	Numerous cortical microvascular lesions related to severe CAA	Meningoencephalitis	30	V/VI	++	1
102-6	M	50	8	1707	57	7	81	2005	Old age, Alzheimer’s disease	A3B3C3	Severe CAA		6	V/VI	++	1
102-7	M	50	8	4374	60	6	82	2005	Old age, Alzheimer’s disease, cerebral atrophy	A1B3C0			16	V/VI	+++	1
102-8	M	50	8	6470	64	10	63	2005	Ischaemic heart disease, coronary artery atherosclerosis	A1B3C1			6	V/VI	+++	1
102-11	M	50	8	142	94	12	88	2008	Bronchopneumonia and mucinous cystadenoma of pancreas (stented), dementia	A3B3C2	Severe CAA		8	V/VI	+	1
102-16	F	225	6	142	111	15	89	2009	Cerebrovascular accident, dementia	A3B3C0	Extensive capillary CAA	Small acute infarct left basal ganglia	Unk	V/VI	+++	1
102-17	F	50	Unk	0	141	13	86	2012	Bronchopneumonia, Alzheimer’s disease	A3B3C3		Small old right parietal infarcts, microvascular lesions entorhinal cortex	7	V/VI	+	2
102-20	M	225	3	430	166	17	82	2014	Alzheimer’s disease	A3B3C2	Extensive capillary CAA		15	V/VI	+++	Unk
102-21	F	50	8	3045	173	18	87	2014	Lower respiratory tract infection, dementia	A3B3C1	Extensive capillary CAA		96	V/VI	+++	1
102-22	M	225	Unk	1313	184	18	74	2015	Alzheimer’s disease	A3B3C3	Extensive capillary CAA		Unk	V/VI	+	2
102-14	M	Placebo	8	0	96	9	64	2008	Alzheimer’s disease	A3B1C0		TDP43+ inclusions, hippocampal sclerosis	10	I/II	−	2
102-15	F	Placebo	Unk	7	104	12	93	2009	Heart failure, ischaemic heart disease, diabetes mellitus, Alzheimer’s disease	A3B3C3	Moderate CAA	Severe arteriolosclerosis/rarefaction of cerebral white matter, several cortical microinfarcts	72	V/VI	−	1
cAD
601	M	n/a	n/a	n/a	n/a	10	68	2000	Advanced Alzheimer’s disease	B3			61	VI	n/a	0
668	F	n/a	n/a	n/a	n/a	15	71	2001	Bronchopneumonia	B3			24	VI	n/a	2
674	M	n/a	n/a	n/a	n/a	3	81	2001	Unk	B3			24	VI	n/a	Unk
679	F	n/a	n/a	n/a	n/a	5	82	2001	Dementia	B3			110	IV	n/a	1
683	M	n/a	n/a	n/a	n/a	5	83	2002	Unk	B3C3			48	V	n/a	0
685	M	n/a	n/a	n/a	n/a	10	74	2001	Perforated benign oesophageal ulcer, bronchopneumonia	B3C2			48	V	n/a	0
703	F	n/a	n/a	n/a	n/a	9	83	2003	Unk	A3B3C2			48	V	n/a	1
705	F	n/a	n/a	n/a	n/a	10	82	2003	Unk	A3B3C3			Unk	V	n/a	1
745	F	n/a	n/a	n/a	n/a	15	84	2006	Sigmoid volvulus, bronchopneumonia	A3B3C3	Moderate CAA	Severe arteriolosclerosis	21	VI	n/a	0
763	F	n/a	n/a	n/a	n/a	9	80	2007	Bronchial pneumonia, fragility of old age, severe dementia	A3B3C3			51	V	n/a	2
765	M	n/a	n/a	n/a	n/a	3	80	2007	Bronchopneumonia	A3B3C2	Moderate CAA		24	IV	n/a	1
CAA
CAA15	M	n/a	n/a	n/a	n/a	n/a	67	2017	Unk	A3B1C1	Severe CAA	Lobar haemorrhage right frontal lobe, remote microvascular lesions	24	I	n/a	Unk

^a Evidence of plaque removal was assessed according to previous methods detailed in Nicoll et al.³